Page last updated: 2024-12-08
ad 20
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
AD 20: designed to reduce toxicity or enhance activity of anticancer drugs [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 159468 |
| MeSH ID | M0150953 |
Synonyms (17)
| Synonym |
|---|
| ccris 3396 |
| 111542-07-5 |
| 2-[[2-(2-methoxyphenyl)acetyl]amino]prop-2-enoic acid |
| ad 20 |
| ad20 |
| o-methoxyphenylacetyl dehydroalanine |
| 2-propenoic acid, 2-(((2-methoxyphenyl)acetyl)amino)- |
| ad-20 |
| tje9ae2975 , |
| unii-tje9ae2975 |
| n-(2-methoxyphenylacetyl)dehydroalanine |
| 2-propenoic acid,2-[[2-(2-methoxyphenyl)acetyl]amino]- |
| DTXSID40149689 |
| 2-((2-(2-methoxyphenyl)acetyl)amino)-2-propenoic acid |
| 2-propenoic acid, 2-((2-(2-methoxyphenyl)acetyl)amino)- |
| (o-methoxyphenylacetyl)dehydroalanine |
| AKOS040745478 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 53.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (53.90) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||